Placebo inhalation solution
Sponsors
United Therapeutics, GlaxoSmithKline, Boehringer Ingelheim, Gerard Turino, Spyryx Biosciences, Inc.
Conditions
Alpha 1-Antitrypsin DeficiencyAsthmaCystic FibrosisEmphysemaHealthyHealthy SmokerPulmonary Disease, Chronic ObstructivePulmonary Hypertension
Phase 1
Phase 2
Efficacy/Safety of HA Inhalation Solution for Hereditary Emphysema in Patients With Alpha-1 Antitrypsin Deficiency
CompletedNCT03114020
Start: 2017-03-22End: 2019-11-12Updated: 2020-04-21
An Efficacy and Safety Study of SPX-101 Inhalation Solution in Subjects With Cystic Fibrosis
CompletedNCT03229252
Start: 2017-08-01End: 2019-06-20Updated: 2019-12-30
Phase 3
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
CompletedNCT00147199
Start: 2005-06-30End: 2007-10-31Updated: 2024-01-02
Nebulized Fluticasone Propionate VS Oral Prednisone in Chinese Pediatric and Adolescent Subjects With an Acute Exacerbation of Asthma
CompletedNCT01687296
Start: 2012-11-12End: 2013-06-21Updated: 2018-06-20
Ipratropium Bromide/Salbutamol Delivered by the Respimat® Inhaler Compared to Ipratropium Bromide Respimat®, COMBIVENT® Inhalation Aerosol and Placebo in Adults With Chronic Obstructive Pulmonary Disease
CompletedNCT02177253
Start: 2002-10-31Updated: 2014-06-27